THE ALBERT EINSTEIN CANCER CENTER and the Montefiore Einstein Center for Cancer Care received a Ruth L. Kirschstein NRSA Institutional Research Training Grant from NIH, which will provide $1.18 million in funding over five years.
Amgen entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia (denosumab), XGEVA (denosumab) and Vectibix (panitumumab) in 48 countries in Asia, South America, Europe, Australia and other regions.
Stem Cell Theranostics and CapellaBio established a cardio-oncology collaboration to discover novel drug therapies to prevent cardiotoxicity associated with various oncology drugs.
Patients are being harmed because FDA doesn't commit sufficient resources to enforce federal requirements for hospitals and manufacturers to report adverse outcomes caused by medical devices, according to Larry Pilot, one of the original authors of FDA's 510(k) device clearance process.
RICHARD ADAMSON received the 2016 Founders Award from the Society of Toxicology.
JOSEPH SMITH JR. received the Huggins Medal from The Society of Urologic Oncology, the society's highest honor, for his lifetime contributions to treatment for patients with genitourinary neoplasms. Smith is a professor of Urologic Surgery at Vanderbilt University Medical Center.
FDA's Class II 510(k) clearance process for medium-risk devices—a category that includes the power morcellator—is inadequate, because it does not focus on risk assessment, according to Bill Vodra, a former associate chief counsel for drugs at FDA.
BHRAMAR MUKHERJEE was appointed associate director for population science research at The University of Michigan Comprehensive Cancer Center, effective Jan. 15, 2016.
JOHN “DREW” RIDGE was elected president of the medical staff at Fox Chase Cancer Center – Temple Health. Ridge serves as chief of Head and Neck Surgery and Louis Della Penna Family Chair in Head and Neck Oncology.
The FDA Office of Criminal Investigations is being asked to determine why the agency has failed to detect the upstaging of cancers in women who had been operated on with a power morcellator.